BidaskClub upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX) from a sell rating to a hold rating in a report released on Monday.

NBIX has been the topic of several other research reports. Oppenheimer set a $105.00 target price on Neurocrine Biosciences and gave the company a buy rating in a research report on Sunday. Cantor Fitzgerald set a $150.00 target price on Neurocrine Biosciences and gave the company a buy rating in a research report on Monday, November 5th. ValuEngine downgraded Neurocrine Biosciences from a strong-buy rating to a buy rating in a research report on Thursday, November 15th. Robert W. Baird decreased their target price on Neurocrine Biosciences from $131.00 to $96.00 and set an outperform rating on the stock in a research report on Thursday, December 13th. Finally, Needham & Company LLC set a $104.00 target price on Neurocrine Biosciences and gave the company a buy rating in a research report on Wednesday, December 12th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $104.62.

NBIX traded down $1.94 during trading on Monday, hitting $83.54. The company’s stock had a trading volume of 15,170 shares, compared to its average volume of 1,525,724. Neurocrine Biosciences has a twelve month low of $64.72 and a twelve month high of $126.98. The firm has a market cap of $6.77 billion, a P/E ratio of -51.51, a PEG ratio of 2.15 and a beta of 1.18.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Monday, November 5th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.48 by $0.04. Neurocrine Biosciences had a return on equity of 2.54% and a net margin of 2.40%. The company had revenue of $151.80 million for the quarter, compared to analyst estimates of $151.51 million. During the same period last year, the company earned ($0.13) earnings per share. Neurocrine Biosciences’s quarterly revenue was up 149.7% compared to the same quarter last year. On average, analysts anticipate that Neurocrine Biosciences will post 0.19 earnings per share for the current fiscal year.

In related news, Director Gary A. Lyons sold 15,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, November 2nd. The stock was sold at an average price of $114.41, for a total transaction of $1,716,150.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Matt Abernethy sold 1,178 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $90.00, for a total value of $106,020.00. Following the transaction, the chief financial officer now owns 1,947 shares in the company, valued at approximately $175,230. The disclosure for this sale can be found here. In the last quarter, insiders have sold 38,925 shares of company stock worth $4,204,191. 4.30% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in NBIX. Federated Investors Inc. PA raised its position in Neurocrine Biosciences by 90.0% in the third quarter. Federated Investors Inc. PA now owns 152,488 shares of the company’s stock valued at $18,748,000 after purchasing an additional 72,224 shares during the period. Rehmann Capital Advisory Group raised its position in Neurocrine Biosciences by 54.7% in the third quarter. Rehmann Capital Advisory Group now owns 557 shares of the company’s stock valued at $68,000 after purchasing an additional 197 shares during the period. Marshall Wace LLP purchased a new stake in Neurocrine Biosciences in the third quarter valued at $9,895,000. Great Lakes Advisors LLC purchased a new stake in Neurocrine Biosciences in the third quarter valued at $9,269,000. Finally, Vanguard Group Inc raised its position in Neurocrine Biosciences by 2.7% in the third quarter. Vanguard Group Inc now owns 7,772,236 shares of the company’s stock valued at $955,597,000 after purchasing an additional 204,065 shares during the period. Hedge funds and other institutional investors own 96.62% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

See Also: Diversification Important in Investing

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.